Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

We assessed the safety, tolerability and efficacy of the immunomodulatory drug, CC-5013 (REVIMID™), in the treatment of patients with metastatic malignant melanoma and other advanced cancers. A total of 20 heavily pretreated patients received a dose-escalating regimen of oral CC-5013. Maximal tolera...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Bartlett, J B, Michael, A, Clarke, I A, Dredge, K, Nicholson, S, Kristeleit, H, Polychronis, A, Pandha, H, Muller, G W, Stirling, D I, Zeldis, J, Dalgleish, A G
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2004
Teme:
Clinical
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2410215/
https://ncbi.nlm.nih.gov/pubmed/14997189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601579
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki